Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability ; volume:84 ; number:3 ; day:14 ; month:3 ; year:2024 ; pages:285-304 ; date:3.2024
Drugs ; 84, Heft 3 (14.3.2024), 285-304, 3.2024
- Urheber
-
Carlson, Alise K.
Amin, Moein
Cohen, Jeffrey A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-024-02011-w
- URN
-
urn:nbn:de:101:1-2406171043168.748985612202
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Carlson, Alise K.
- Amin, Moein
- Cohen, Jeffrey A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
Direct, indirect and longitudinal immunological effects of anti-CD20 mediated B cell depletion in Multiple Sclerosis
Pharmakokinetik des monoklonalen anti-CD20 Antikörpers Rituximab bei aggressiven CD20 positiven B-Zell-Lymphomen
Pharmacology
Pharmacology
Pharmacology
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
Direct, indirect and longitudinal immunological effects of anti-CD20 mediated B cell depletion in Multiple Sclerosis
Pharmakokinetik des monoklonalen anti-CD20 Antikörpers Rituximab bei aggressiven CD20 positiven B-Zell-Lymphomen
Pharmacology
Pharmacology
Pharmacology
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
Direct, indirect and longitudinal immunological effects of anti-CD20 mediated B cell depletion in Multiple Sclerosis
Pharmakokinetik des monoklonalen anti-CD20 Antikörpers Rituximab bei aggressiven CD20 positiven B-Zell-Lymphomen
Pharmacology
Pharmacology
Pharmacology
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis